INTRODUCTION
Lymphatic anomalies encompass a spectrum of diseases with marked heterogeneity. In 2014, the International Society for the Study of Vascular Anomalies (ISSVA) reclassified lymphatic anomalies into simple and complex. 1 Complex lymphatic anomalies, which include generalized lymphatic anomaly (GLA), Gorham-Stout disease (GSD), and channel type lymphatic malformation (CTLM), have more systemic involvement (soft tissue, bone, spleen, other viscera, as well as effusions) and have significant impact on morbidity, mortality, and overall quality of life. Kaposiform lymphangiomatosis (KLA) is a more recently characterized systemic and frequently aggressive lymphatic anomaly, typically presenting in childhood or early adulthood ( Fig. 1) (refs. [2] [3] [4] [5] ). KLA is clinically heterogeneous. Frequently there is thoracic involvement, and the abdomen can also be diffusely involved, as well as the spleen, gastrointestinal tract, bone, and other organs. Thoracic involvement in KLA is more extensive than in GLA, and includes mediastinal, pleural, and parenchymal pulmonary disease, often with recurrent pleural and/or pericardial effusions. Hemostatic anomalies, marked by coagulopathy and intralesional hemorrhage, are common and can be rapidly progressive and lethal. A defining feature of KLA is the presence of variably abundant foci of spindled lymphatic endothelial cells with incomplete canalization accompanying abnormal lymphatic channels of varying size. Although similar spindled endothelial cells are also found in kaposiform hemangioendothelioma (KHE), KHE is a localized vascular tumor with a distinct histopathology commonly seen in infants and toddlers and often associated with coagulopathy (Kasabach-Merritt phenomenon). 6 A genetic cause for these complex lymphatic anomalies has not yet been identified, although a somatic activating NRAS variant (p.Q61R) was recently identified in a single case of GLA, and shown to have a pathogenic effect on the lymphatic endothelium. 7 Despite multimodal therapy, the overall prognosis of KLA remains poor, with an overall survival of 34% (refs. 3, 4 ). Identification of a causative variant would enable more efficacious targeted therapies for this aggressive disease.
Recently, several vascular anomalies have been shown to be caused by somatic activating variants in the MAPK and PI3K/ AKT pathways (Table S1 ). We hypothesized that this might also be the case for KLA. Although we had previously identified hotspot variants in PIK3CA as a cause of localized lymphatic anomalies and combined vascular malformations with a lymphatic component, 8, 9 we did not find similar variants in KLA. Hence, we performed exome sequencing of tissue specimens-both lesional and uninvolved-from individuals with KLA. The University of Calgary Institutional Review Board and the Committee on Clinical Investigation of Boston Children's Hospital approved this study. All participants provided informed consent to participate, including, for those whose photos are used, consent to publish photos.
MATERIALS AND METHODS

Exome sequencing and analysis
We performed exome sequencing of five KLA tumor samples as well as uninvolved tissue from three of those five individuals. Thin sections were scraped from diagnostic formalin-fixed paraffin-embedded (FFPE) tissue blocks, which had been obtained either at biopsy (2/5 cases), or at autopsy (3/5 cases We analyzed the exome sequences based on the Genome Analysis Toolkit (GATK) Best Practices for Somatic Short Variant Discovery. 10 Briefly, sequence reads were aligned to the reference human genome (GRCh37) using the Burrows-Wheeler Aligner MEM algorithm (BWA-MEM), 11 duplicates were marked using Picard, and base quality scores were recalibrated using GATK (see Supplementary Methods for all commands and arguments used). For each exome, 79-99% of target bases were covered at least 15-fold, and 42-92% of target bases were covered at least 50-fold, by unique reads with a minimum base quality score of 20 (Table S2) .
We used Mutect2 in GATK4 to identify somatic variants, with a "panel of normals" created from 11 1000 Genomes participants, 12 and using the gnomAD database 13 as a "germline-resource." For the three paired samples (KLA1, KLA2, and KLA3), we used the default Mutect2 parameters, with the exception of adjusting the "-af-of-alleles-not-inresource" to 0.0000025, as recommended in the GATK4 Mutect2 Tutorial provided by the Broad Institute. We included in our analysis all somatic variant calls passing the standard Mutect2 filters. For the two unpaired tumor samples (KLA4 and KLA5), we ran Mutect2 in "tumor-only" mode, and ignored the "germline_risk" filter, including in our analysis any calls in which that was the only filter applied. The resulting somatic variant calls were then annotated using ANNOVAR. 14 FFPE tissue blocks or unstained glass slides of diagnostic specimens, collected previously during biopsy, were obtained from six additional individuals. Thin sections were scraped from the blocks or slides (for the five tumor samples included in the exome analysis, new thin sections were scraped from the same FFPE tissue blocks used for exome analysis), and DNA was extracted using a GeneRead FFPE DNA Extraction Kit (Qiagen), with the only modification to the kit protocol being that the Proteinase K digestion was extended overnight. Digital polymerase chain reaction (dPCR) was performed using a fully validated TaqMan NRAS p.Q61R assay (Applied Biosystems by Thermo Fisher Scientific, Waltham, MA, USA; assay ID: C_44193858_10). Genomic DNA was diluted so that the concentration of target DNA was 200-2000 copies/uL. PCR reaction mix was prepared per manufacturer's protocol and 14.5 uL was loaded on each QuantStudio™ 3D Digital PCR chip v2 (Thermo Fisher Scientific). Digital chips were run on a ProFlex™ 2× Flat PCR thermocycler (Applied Biosystems by Thermo Fisher Scientific) with the following cycling conditions: 96°C 10 minutes, then 39 cycles of 60°C for 2 minutes, followed by 98°C 30 seconds, then a final elongation step at 60°C 2 minutes and 10°C hold. Digital imaging was performed on the QuantStudio™ 3D Digital PCR Instrument and results were analyzed using the QuantStudio™ 3D Analysis Suite Software version 3.1.2 (Applied Biosystems by Thermo Fisher Scientific).
Additional analyses in KLA2
We did not identify the NRAS p.Q61R variant in one individual, KLA2, despite testing two independent lesional tissue samples, and despite the fact that no clinical or histopathological differences were apparent between this individual and the other ten participants. We compared ballele frequencies between the lesional and control samples to look for regions of loss of heterozygosity, and used Lumpy 15 to look for large structural variants or copy-number variations ( Figure S1 ; commands in Supplementary Methods). We searched the exome data of KLA2 for other somatic hotspot variants, 16 and for rare (i.e., frequency <0.001 in gnomAD database), nonsynonymous variants in other genes that have previously been implicated in vascular anomalies (Table S1) . For this search, we loosened the stringency of variant calling, looking at all the raw calls output by Mutect2 (i.e., without filtering), and then investigating any calls of interest in the Integrative Genomics Viewer (IGV) to exclude mapping errors or sequencing artifacts. Additionally, for this search, we looked at germline variants in the lesional tissue sample, called using the HaplotypeCaller from GATK4, following their recommended best practices. 10 
RESULTS
Identification of consensus NRAS variant
We identified a single gene-NRAS-in which three or more of the KLA participants had a novel (i.e., not previously identified in the gnomAD database), nonsynonymous, Fig. 2 ). Visual inspection in IGV 17 revealed that it was also present in a fourth lesional sample at 4% (though with only three sequence reads supporting the variant call, which is likely why it was not identified by the variant calling software) ( Table 1) . This variant was also present on 20/105 reads (19%) from the KLA5 RNA sequencing data. No variant reads were identified in any of the three uninvolved tissue samples. We performed digital PCR (dPCR) (and, in one case, a targeted high-throughput sequencing panel) to validate that this was a true variant (as opposed to a sequencing error), and to look for the variant in additional KLA samples. This sensitive variant detection method confirmed the presence of the NRAS p.Q61R variant in all four positive exome tumors, and confirmed the absence of the variant in the single negative exome tumor (KLA2). In addition, the variant was identified in all six new KLA tumor samples, at levels ranging from 1% to 8% (Table 1, Fig. 2 ).
NRAS p.Q61R screen in kaposiform hemangioendothelioma
We also used dPCR to screen for the NRAS p.Q61R variant in kaposiform hemangioendothelioma (KHE). We tested six KHE tumor samples for the NRAS p.Q61R variant, and all were negative (Table S3 ).
Additional analyses in KLA2
We did not identify the NRAS p.Q61R variant in one individual, KLA2, despite testing two independent lesional tissue samples. Using Lumpy, 15 we also excluded large structural variants, copy-number variations (100 bp-10 kbp in size), or loss of heterozygosity in the exome data of this individual ( Figure S1 ; commands in Supplementary Methods). No somatic or germline known hotspot variants were found, but from the list of vascular anomaly-associated genes (Table S1) , we identified a missense variant in GNAQ (c.175 A>C, p.M59L), and two variants-a missense and a nonsense -in TEK (c.508G>C, p.V66L and c.340C>T, p.R114X).
The GNAQ variant identified in KLA2 (c.175A>C, p.M59L) has not previously been reported in the gnomAD or ClinVar databases, and appears only once in the COSMIC database (COSM6304069). However, it was recently reported in five cases of acral melanoma. 18 Though the variant was present on 25 sequencing reads in the KLA2 lesional exome, there were several potential problems with the call (Figure S2) . A BLAST search of the reads carrying the putative variant revealed that they could also map to an intergenic region of chromosome 2, with a single mismatch corresponding to a common polymorphism (rs3730153; minor allele frequency 22%). It is therefore likely that participant KLA2 carries the chromosome 2 germline polymorphism, and that the GNAQ variant represents a low-level artifact in both the lesional and uninvolved exomes due to mismapping of a small proportion of reads. 
DISCUSSION
Our finding of a somatic NRAS p.Q61R variant in the lesional tissue in 10 of 11 individuals with KLA strongly implicates this variant in the pathogenesis of the disease, and suggests an important role for NRAS signaling in lymphatic vessel development and proliferation. NRAS is a proto-oncogene that encodes a small GTPase that normally functions to regulate cell proliferation via the MAPK and PI3K/AKT signaling pathways [19] [20] [21] -consistent with the pathways in which somatic variants in other vascular anomalies have so far been identified (Table S1 ). It is a member of the Ras gene family, which also includes HRAS and KRAS, and which are frequently altered in human cancers. [19] [20] [21] In particular, NRAS variants are identified in more than 20% of melanomas. 22 Three codons-12, 13, and 61-are variation hotspots (being variant in 74, 41, and 422 tumors, respectively, in a survey of 11,119 tumors 16 ). Variants at each of these three sites result in a constitutively active NRAS protein and therefore, constitutive activation of downstream signaling pathways, resulting in unchecked cell proliferation. 21 In addition to the prevalence of these variants in human cancers, somatic activating RAS variants have been identified in several benign cutaneous, skeletal, and vascular disorders (Table S4 ). Codon 61 NRAS variants, specifically, have been identified in epidermal nevi (MIM 162900) (ref. 23 ), multiple congenital melanocytic nevi (CMNS [MIM 137550]) and neurocutaneous melanosis (NCMS [MIM 249400]) (ref. 24 ), cutaneous skeletal hypophosphatemia syndrome (CSHS), 25 and vascular anomalies including pyogenic granuloma. 26, 27 The presence of the NRAS p.Q61R variant in 10 of 11 tested KLA samples, therefore, adds KLA to the list of mosaic conditions linked to postzygotic activating NRAS variants, and to the even broader list of phenotypes associated with somatic variants in the RAS-MAPK and PI3K/AKT pathways. In general, the clinical and histopathologic similarities in all 11 patients seemed to justify a diagnosis of KLA. The single NRAS p.Q61R-negative individual therefore suggests the possibility of some locus or allelic heterogeneity within KLA.
Germline alterations in components of the RAS/MAPK pathway, including NRAS, cause a group of syndromes known as RASopathies, including neurofibromatosis type 1, Noonan syndrome, Costello syndrome, capillary malformationarteriovenous malformation syndrome, and others. 28 The NRAS p.Q61R variant has not been identified in any of these syndromes. Additionally, germline RASopathies are associated with craniofacial, neurodevelopmental, and other shared phenotypic features that are not observed in KLA or other somatic mosaic conditions linked to variants in the RAS-MAPK pathway, which are often collectively referred to as somatic mosaic RASopathies.
The NRAS p.Q61R variant has recently been reported in a single case of generalized lymphatic anomaly (GLA), formerly known as diffuse lymphangiomatosis. 7 The distinction of KLA from GLA has only recently been made. 3, 4 While both are characterized by a generalized lymphatic anomaly of soft tissue that often includes viscera and bone, KLA is more commonly marked by significant coagulopathy, a more aggressive clinical course, and is pathologically distinct as defined by the presence of a spindled lymphatic endothelial component. 3, 4 It is of interest that the case of GLA with an NRAS p.Q61R variant reported by Manevitz-Mendelson et al. had histopathology that included dispersed spindle-like cells, which made the authors consider the possibility of KLA, although the lack of cutaneous involvement and consumptive coagulopathy prompted the authors to make a diagnosis of GLA. 7 As we did not examine any cases of GLA for this study, it is possible that these two forms of generalized lymphatic disorders share a common genetic etiology. We would, therefore, recommend that genetic screening for this NRAS variant be performed in all individuals with aggressive and/or disseminated lymphatic anomalies.
Interestingly, in preliminary functional analyses by Manevitz-Mendelson et al., artificial overexpression of the NRAS p.Q61R variant allele in zebrafish actually impaired lymphatic development. 7 This raises the possibility that a mosaic microenvironment with wild-type lymphatic endothelial cells may be necessary to cause a proliferative phenotype in vivo. Alternatively, the observed effects may be the result of artificial expression under a pan-vascular promoter, such as fli-1, and/or a dosage effect from NRAS overexpression. 29 It is also unclear how this NRAS variant is associated with such divergent biologic behavior as seen in metastatic melanoma, KLA, and more banal anomalies. KLA is heterogeneous, both in disease progression and particularly in the response to treatment. While we did screen our exome data to look for potential permissive alleles and genetic modifiers, no obvious variants were detected in this small subset. Additional work, particularly in model organisms, will be needed to further explore these possibilities.
KLA shares some characteristics with another vascular anomaly, KHE. Though they differ clinically as KHE is a more localized, infiltrative tumor seen in infancy, they share the presence of spindled cells with abnormal lymphatic channels and a propensity for significant hemorrhagic complications. 6 The cause of KHE is also not known, but recently, a GNA14 p. Q205L variant was identified in a single KHE and a related entity, tufted angioma (MIM 607859) (ref. 30 ). Our finding that the consensus KLA variant is absent from six KHE samples indicates that KLA and KHE are likely also genetically separate entities. Whether other NRAS variants occur in KHE, or whether the GNA14 variant is recurrent, remains to be determined.
In the single NRAS p.Q61R-negative individual (KLA2), we identified putative somatic variants in two genes associated with other vascular anomalies-GNAQ and TEK (Table S1 ). Though the GNAQ variant (c.175 A>C, p.M59L) was also reported in a study of acral melanoma, 18 we showed that, in our data, it was likely a false positive variant call, representing the mismapping of a small number of reads spanning a polymorphism on chromosome 2 (see Results, Additional analyses in KLA2). We note that the previous report of this variant in acral melanoma 18 identified the variant in 5 of 85 individuals by high-throughput sequencing of a panel of candidate genes, but that the authors did not validate the variant call by a second method. The single report of this variant in the COSMIC database was also not validated by a second method (see COSMIC study ID COSU660). It is, therefore, possible that these results were also confounded by the presence of this chromosome 2 polymorphism, suggesting that the GNAQ c.175A>C, p.M59L variant should be carefully scrutinized if it is identified in future sequencing studies. This highlights the importance of secondary validation of highthroughput sequencing results, especially for somatic variant calls that may be present on a low number of sequencing reads. In addition, given the high population frequency of the confounding chromosome 2 polymorphism, this false positive variant call would likely have been replicated in the panel of normals if a larger number of individuals had been included (we only included 11, while the recommended minimum is 40), emphasizing the benefit of using a large panel of normals in such analyses.
The two TEK variants identified in KLA2-c.508G>C, p. V66L and c.340C>T, p.R114X-are located in the extracellular domain and include a loss-of-function allele, whereas the TEK variants implicated in venous malformations are gain-of-function variants in the intracellular portion of the protein (amino acid positions 849, 897, 914) (refs. [31] [32] [33] ). However, TEK is likely to be haploinsufficient, 13 and inherited heterozygous loss-of-function TEK variants cause primary congenital glaucoma (MIM 617272) by disrupting vascular development in the anterior chamber. 34 It cannot be excluded that a very low-level somatic nonsense variant could have pathogenic effects on lymphatic endothelial organization, causing a spindled/kaposiform phenotype. The p.V66L and p. R114X variants were found at very low levels (2/94 and 8/ 739 sequencing reads, respectively) in the lesional exome, and were not seen in the control exome, but because they were not found in any other individuals, we did not pursue further validation. It, therefore, remains possible that these are merely false positive variant calls. Nevertheless, TEK represents a potential candidate for screening if additional NRAS p.Q61Rnegative individuals with KLA are identified.
Treatment of KLA patients is challenging and the responses are variable. Multimodal treatment is directed toward minimizing disease progression, hemorrhagic complications, and lymphatic chylous effusions. Primary resection is not recommended because it can lead to rapid decompensation. 3 Supportive therapy is essential in the treatment of KLA patients and this may require correcting the coagulopathy and draining of effusions (pleural, pericardial, and ascites) when clinically necessary. Despite these treatment efforts, the fiveyear survival rate was 51%, and the overall survival was just 34% in the initial series of 20 patients. 3 Since the demonstration of the safety and efficacy of sirolimus therapy for complicated vascular anomalies, 35 and our discovery of PIK3CA activating variants as a cause of simple and combined lymphatic malformations, 8, 9 many patients, including those with KLA, have regularly been treated with this mTOR inhibitor. The effect of mTOR inhibition in KLA is mixed, with many patients requiring concurrent antiproliferative therapies, including vincristine, methylprednisolone, thalidomide, and/or interferon. 3, 4 Studies are presently in preparation to update the survival rate following the introduction of sirolimus treatment.
Identification of the NRAS p.Q61R variant in KLA provides a means for a more targeted treatment approach. As RAS activation also activates PI3K/mTOR signaling, it is not surprising that patients would have some benefit from sirolimus therapy. However, current therapies do not effectively target RAS/MAPK signaling. Fortunately, many efforts are underway to develop novel treatments for NRASvariant cancers such as melanoma. These have proven difficult to treat, presumably due to the high affinity of RAS for GTP. [36] [37] [38] Nevertheless, progress is being made-for example, clinical trials of binimetinib, a MEK1 and MEK2 inhibitor, have shown small benefits in NRAS-variant melanoma cohorts, 39 and may be more efficacious when combined with immunotherapy. 40 Inhibitors of additional downstream components of NRAS signaling, including RAF and ERKs, are also being clinically tested. 38 In conclusion, we have shown that somatic NRAS p.Q61R variants are recurrent in KLA, providing not only a more specific means for diagnosis, but also a new approach for more effective targeted treatments. We have shown that this variant is not found in KHE (at least not as commonly as in KLA), further distinguishing these two disorders. We have also potentially identified (though not validated) a novel missense (p.V66L) and a novel nonsense (p.R114X) variant in TEK, in the lone NRAS p.Q61R-negative patient in our cohort, which represents a candidate for consideration if additional p.Q61R-negative patients are found. Finally, we have highlighted a potentially recurrent false positive GNAQ variant (c.175 A>C, p.M59L) that should be carefully evaluated whenever it appears as a candidate in highthroughput sequencing studies.
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